mRNA shouldn’t have a party affiliation

Published



Cancer medicine had an extraordinary weekend in Madrid.

At the European Society for Medical Oncology Congress, Amgen’s Imdelltra, added to AstraZeneca’s Imfinzi as maintenance therapy for extensive-stage small-cell lung cancer, cut the risk of death by 58%. Median survival rose from just under 13 months to a little over 21 months.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.